BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36165348)

  • 1. Breast PET/MRI Hybrid Imaging and Targeted Tracers.
    Romeo V; Helbich TH; Pinker K
    J Magn Reson Imaging; 2023 Feb; 57(2):370-386. PubMed ID: 36165348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [
    Mirshahvalad SA; Eisazadeh R; Shahbazi-Akbari M; Pirich C; Beheshti M
    Semin Nucl Med; 2024 Jan; 54(1):171-180. PubMed ID: 37752032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/MRI of the breast.
    Plecha DM; Faulhaber P
    Eur J Radiol; 2017 Sep; 94():A26-A34. PubMed ID: 28549570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multiparametric and molecular imaging of breast tumors with MRI and PET/MRI].
    Pinker K; Marino MA; Dr Meyer-Baese A; Helbich TH
    Radiologe; 2016 Jul; 56(7):612-21. PubMed ID: 27364727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer.
    Backhaus P; Burg MC; Roll W; Büther F; Breyholz HJ; Weigel S; Heindel W; Pixberg M; Barth P; Tio J; Schäfers M
    Radiology; 2022 Jan; 302(1):39-47. PubMed ID: 34636633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid
    Goorts B; Vöö S; van Nijnatten TJA; Kooreman LFS; de Boer M; Keymeulen KBMI; Aarnoutse R; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1796-1805. PubMed ID: 28600647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[
    Sonni I; Minamimoto R; Baratto L; Gambhir SS; Loening AM; Vasanawala SS; Iagaru A
    Mol Imaging Biol; 2020 Apr; 22(2):397-406. PubMed ID: 31236756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PET-CT and PET-MRI of the prostate : From
    Knorr K; Eiber M; Maurer T; Wester HJ; Scheidhauer K
    Radiologe; 2017 Aug; 57(8):631-636. PubMed ID: 28688023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AI-Enhanced PET and MR Imaging for Patients with Breast Cancer.
    Romeo V; Moy L; Pinker K
    PET Clin; 2023 Oct; 18(4):567-575. PubMed ID: 37336693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of
    Kirchner J; Martin O; Umutlu L; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Gauler T; Theurer S; Antke C; Esposito I; Kinner S; Schaarschmidt BM; Kowall B; Lütke-Brintrup D; Stang A; Becker AS; Antoch G; Buchbender C
    Eur J Radiol; 2020 Jul; 128():108975. PubMed ID: 32371185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.
    Botsikas D; Kalovidouri A; Becker M; Copercini M; Djema DA; Bodmer A; Monnier S; Becker CD; Montet X; Delattre BM; Ratib O; Garibotto V; Tabouret-Viaud C
    Eur Radiol; 2016 Jul; 26(7):2297-307. PubMed ID: 26477029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical advances in PET-MRI for breast cancer.
    Fowler AM; Strigel RM
    Lancet Oncol; 2022 Jan; 23(1):e32-e43. PubMed ID: 34973230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid imaging with PET/MRI: ready for clinical routine?
    Ferda J
    Eur J Radiol; 2017 Sep; 94():A1-A2. PubMed ID: 28551301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET Imaging for Breast Cancer.
    Fowler AM; Cho SY
    Radiol Clin North Am; 2021 Sep; 59(5):725-735. PubMed ID: 34392915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-18 FDG PET/MRI findings of primary breast lymphoma in two cases: FDG PET/MRI findings of primary breast lymphoma.
    Kong EJ; Cho IH
    Clin Imaging; 2015; 39(4):682-4. PubMed ID: 25748090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.